Expected Trial Completion for AVT16 vs Entyvio
Aug 31, 2026, 4:00:00 AM — trial completion
Summary
Alvotech Swiss AG is conducting a Phase 3 clinical trial comparing AVT16, a proposed biosimilar, to Entyvio (vedolizumab) in terms of efficacy, safety, and immunogenicity. The trial, which began in September 2024 and is currently recruiting, is expected to complete on August 31, 2026. Entyvio is a monoclonal antibody used to treat ulcerative colitis and Crohn's disease. AVT16 aims to offer a lower-cost alternative in the inflammatory bowel disease market.
Company
ALVOTECH (ALVO)NASDAQ — Healthcare: Manufacturing, Drug Manufacturers - Specialty & Generic: Biological Products (No Disgnostic Substances)
www.alvotech.comSimilar Events
Phase 1 Clinical Trial Completion: AVT80 vs Entyvio
Alvotech Swiss AG is conducting a Phase 1 clinical trial (NCT06732804) comparing AVT80, a proposed biosimilar to Entyvio (vedolizumab), with the reference product. The study focuses on comparative pharmacokinetics, safety, immunogenicity, and tolerability in healthy subjects. The trial is expected to complete on October 1, 2025. Entyvio is a monoclonal antibody used for inflammatory bowel diseases, and AVT80 aims to expand biosimilar options in this therapeutic area.
trial completionPhase 2 Trial Completion for AVTX-009 in Hidradenitis Suppurativa
Avalo Therapeutics is conducting a Phase 2 randomized, double-blind, placebo-controlled trial of AVTX-009 in patients with moderate to severe hidradenitis suppurativa. The study, which began in September 2024, is expected to complete by July 1, 2026. AVTX-009 is an investigational therapy targeting inflammatory pathways in this chronic skin condition. The trial will enroll 180 participants and assess efficacy and safety across two dosing regimens.
trial completionVALIANT Clinical Trial Completion
Upstream Bio Inc. is expected to complete the VALIANT Phase 2 clinical trial of verekitug (UPB-101) in adults with severe asthma on June 11, 2026. The multicenter, randomized, placebo-controlled study aims to enroll 436 participants to evaluate the efficacy and safety of subcutaneous verekitug at various dosing regimens. The trial's outcome will inform further development of verekitug, a biologic targeting severe asthma.
trial completionPhase 3 Trial Completion: ATEV vs AVF in Female ESRD Patients
Humacyte, Inc. is conducting a Phase 3 clinical trial (NCT05908084) comparing its investigational bioengineered blood vessel (ATEV) to arteriovenous fistula (AVF) in female patients with end-stage renal disease (ESRD) requiring hemodialysis. The trial, which began in September 2023, is expected to complete by October 1, 2027. ATEV is a regenerative vascular graft designed as an alternative to traditional AVF for vascular access in dialysis. The study will enroll approximately 150 patients and assess efficacy and safety endpoints over 12 months, with a long-term extension for those with patent access at one year.
trial completion